Modeling the impact and cost-effectiveness of opioid agonist treatments to reduce the negative consequences of incarceration on HIV and TB transmission in Eastern Europe and Central Asia

对阿片类激动剂治疗的影响和成本效益进行建模,以减少监禁对东欧和中亚艾滋病毒和结核病传播的负面影响

基本信息

  • 批准号:
    10013670
  • 负责人:
  • 金额:
    $ 21.84万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-09-30 至 2022-08-31
  • 项目状态:
    已结题

项目摘要

HIV incidence and mortality has decreased globally, but has increased in Eastern Europe and Central Asia (EECA), where the HIV epidemics are fueled primarily by injecting drug use (IDU), mostly of opioids. Furthermore, TB is increasingly linked to HIV infection and IDU, with TB rates increasing and being the main cause of death among people with HIV (PWH) in EECA. Harsh criminalization of drug use in EECA results in extraordinarily high incarceration rates of people who inject drugs (PWID), whose HIV and TB are amplified by high risk behaviors for HIV and overcrowding for TB. Our new data from a global meta-analysis shows that incarceration increases HIV acquisition risk 81% in PWID, and our findings from Ukraine suggest that 28%– 55% of new HIV infections among PWID are attributable to the heightened risk behavior that occurs among PWID recently or ever incarcerated. Furthermore, our recent statistical analyses suggest that the burden of TB in Ukraine is strongly associated with years of incarceration, particularly among PWID with HIV. An effective strategy for tackling the syndemics of incarceration, HIV and TB transmission among PWID in EECA should include opioid agonist treatments (OAT) with methadone or buprenorphine. These effective treatments reduce the frequency of injecting and the risk of HIV acquisition. OAT also improves HIV and TB treatment outcomes and reduces criminal activity, and so could also reduce HIV and TB transmission through reducing the detrimental effect of incarceration and improving the preventative benefits of OAT itself. Scaled up OAT in the community and prison would be especially effective if linked with HIV and TB treatment scale-up. The aim of this project is to develop and testing new modeling strategies to evaluate the impact and cost- effectiveness of scaling-up OAT in criminal justice settings in Ukraine and Kyrgyzstan where we have collected considerable data. To capture the full benefits of OAT in prison, we will also estimate the contribution of incarceration to HIV and TB transmission among PWID and the general population in both countries. We will build on data from our existing implementation science research (R01 DA029910, the MATLINK strategy), in which we have introduced (Ukraine) or expanded (Kyrgyzstan) OAT provision to prisoners with OUD, including linkage to OAT following release to capture this particular high-risk period. We will use data on outcomes from MATLINK and related studies and collected cost data to project the impact and cost-effectiveness of scaling-up prison-based OAT (using MATLINK) with linkage to community OAT after release, incorporating the direct prevention benefits on HIV transmission in PWID and general population and secondary benefits through improving HIV and TB treatment outcomes and reducing incarceration. Findings can be used to guide policies throughout EECA and other settings where HIV is concentrated in PWID.
全球艾滋病毒发病率和死亡率有所下降,但东欧和中亚有所上升 (EECA),其中艾滋病毒流行病主要由注射毒品(IDU)推动,主要是阿片类药物。 此外,结核病越来越多地与艾滋病毒感染和注射吸毒有关,结核病发病率不断上升, EECA艾滋病毒感染者(PWH)的死亡原因。在EECA中,对吸毒的严厉定罪导致 注射毒品者(PWID)的监禁率非常高,他们的艾滋病毒和结核病被放大, 艾滋病的高危行为和过度拥挤的结核病。我们来自全球荟萃分析的新数据显示, 在PWID中,监禁增加了81%的艾滋病毒感染风险,我们在乌克兰的研究结果表明, 在PWID中,55%的新艾滋病毒感染可归因于发生在以下人群中的高危行为: 最近或曾经被监禁过。此外,我们最近的统计分析表明, 在乌克兰,与多年监禁密切相关,特别是在感染艾滋病毒的PWID中。 2004年在残疾妇女中解决监禁、艾滋病毒和结核病传播的有效战略 EECA应包括使用美沙酮或丁丙诺啡的阿片类激动剂治疗(OAT)。这些有效 治疗减少了注射频率和感染艾滋病毒的风险。OAT还可以改善艾滋病毒和结核病 治疗结果,减少犯罪活动,因此也可以减少艾滋病毒和结核病的传播, 减少监禁的有害影响,提高OAT本身的预防效益。扩大 社区和监狱中的OAT如果与扩大艾滋病毒和结核病治疗相联系,将特别有效。 该项目的目的是开发和测试新的建模策略,以评估影响和成本- 在乌克兰和吉尔吉斯斯坦的刑事司法环境中扩大OAT的有效性, 相当可观的数据。为全面评估审裁处在监狱所带来的效益,我们亦会估计 在这两个国家,监禁与艾滋病毒和结核病在PWID和普通人群中的传播有关。我们将 基于我们现有的实施科学研究(R 01 DA 029910,MATLINK战略)的数据, 我们已经向患有OUD的囚犯提供(乌克兰)或扩大(吉尔吉斯斯坦)OAT,包括 在发布后与OAT联系,以捕捉这一特定的高风险时期。我们将使用数据的结果, MATLINK和相关研究,并收集成本数据,以预测扩大规模的影响和成本效益 以监狱为基础的审裁处(使用MATLINK),与释放后的社区审裁处挂钩, 预防艾滋病毒在艾滋病感染者和一般人群中传播的好处,以及通过以下途径获得的次级好处: 改善艾滋病毒和结核病治疗结果并减少监禁。调查结果可用于指导政策 在整个EECA和其他艾滋病毒集中在PWID的环境中。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

FREDERICK LEWIS ALTICE其他文献

FREDERICK LEWIS ALTICE的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('FREDERICK LEWIS ALTICE', 18)}}的其他基金

Prison Interventions and HIV Prevention Collaboration
监狱干预和艾滋病毒预防合作
  • 批准号:
    10548569
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
Innovations in Implementing Decentralized HIV Services in Peru
秘鲁实施分散式艾滋病毒服务的创新
  • 批准号:
    10762842
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
Reducing Stigma in People Who Inject Drugs with HIV Using a Rapid Start Antiretroviral Therapy Intervention
使用快速启动抗逆转录病毒治疗干预措施减少艾滋病毒注射者的耻辱
  • 批准号:
    10756389
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
Georgian Implementation Science Fogarty Training Program (GIFT)
格鲁吉亚实施科学福格蒂培训计划 (GIFT)
  • 批准号:
    10688700
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
Expanding Medication Assisted Therapies in Central Asia
在中亚扩大药物辅助治疗
  • 批准号:
    10693856
  • 财政年份:
    2022
  • 资助金额:
    $ 21.84万
  • 项目类别:
Expanding Medication Assisted Therapies in Central Asia
在中亚扩大药物辅助治疗
  • 批准号:
    10403273
  • 财政年份:
    2022
  • 资助金额:
    $ 21.84万
  • 项目类别:
Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings
将成瘾和传染病服务纳入农村地区的初级保健
  • 批准号:
    10670120
  • 财政年份:
    2021
  • 资助金额:
    $ 21.84万
  • 项目类别:
Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings
将成瘾和传染病服务纳入农村地区的初级保健
  • 批准号:
    10311425
  • 财政年份:
    2021
  • 资助金额:
    $ 21.84万
  • 项目类别:
Integrating Addiction and Infectious Diseases Services into Primary Care in Rural Settings
将成瘾和传染病服务纳入农村地区的初级保健
  • 批准号:
    10453688
  • 财政年份:
    2021
  • 资助金额:
    $ 21.84万
  • 项目类别:
Malaysian Implementation Science Training (MIST) Program in HIV
马来西亚艾滋病毒实施科学培训(MIST)计划
  • 批准号:
    10358577
  • 财政年份:
    2020
  • 资助金额:
    $ 21.84万
  • 项目类别:

相似海外基金

Unraveling the Dynamics of International Accounting: Exploring the Impact of IFRS Adoption on Firms' Financial Reporting and Business Strategies
揭示国际会计的动态:探索采用 IFRS 对公司财务报告和业务战略的影响
  • 批准号:
    24K16488
  • 财政年份:
    2024
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Mighty Accounting - Accountancy Automation for 1-person limited companies.
Mighty Accounting - 1 人有限公司的会计自动化。
  • 批准号:
    10100360
  • 财政年份:
    2024
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Collaborative R&D
Accounting for the Fall of Silver? Western exchange banking practice, 1870-1910
白银下跌的原因是什么?
  • 批准号:
    24K04974
  • 财政年份:
    2024
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
A New Direction in Accounting Education for IT Human Resources
IT人力资源会计教育的新方向
  • 批准号:
    23K01686
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An empirical and theoretical study of the double-accounting system in 19th-century American and British public utility companies
19世纪美国和英国公用事业公司双重会计制度的实证和理论研究
  • 批准号:
    23K01692
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
An Empirical Analysis of the Value Effect: An Accounting Viewpoint
价值效应的实证分析:会计观点
  • 批准号:
    23K01695
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Accounting model for improving performance on the health and productivity management
提高健康和生产力管理绩效的会计模型
  • 批准号:
    23K01713
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
CPS: Medium: Making Every Drop Count: Accounting for Spatiotemporal Variability of Water Needs for Proactive Scheduling of Variable Rate Irrigation Systems
CPS:中:让每一滴水都发挥作用:考虑用水需求的时空变化,主动调度可变速率灌溉系统
  • 批准号:
    2312319
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Standard Grant
New Role of Not-for-Profit Entities and Their Accounting Standards to Be Unified
非营利实体的新角色及其会计准则将统一
  • 批准号:
    23K01715
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Improving Age- and Cause-Specific Under-Five Mortality Rates (ACSU5MR) by Systematically Accounting Measurement Errors to Inform Child Survival Decision Making in Low Income Countries
通过系统地核算测量误差来改善特定年龄和特定原因的五岁以下死亡率 (ACSU5MR),为低收入国家的儿童生存决策提供信息
  • 批准号:
    10585388
  • 财政年份:
    2023
  • 资助金额:
    $ 21.84万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了